210 related articles for article (PubMed ID: 11926125)
1. Live bacteria as anticancer agents and tumor-selective protein delivery vectors.
Bermudes D; Zheng LM; King IC
Curr Opin Drug Discov Devel; 2002 Mar; 5(2):194-9. PubMed ID: 11926125
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001.
Cunningham C; Nemunaitis J
Hum Gene Ther; 2001 Aug; 12(12):1594-6. PubMed ID: 11529249
[TBL] [Abstract][Full Text] [Related]
3. Tumor-targeted Salmonella typhimurium overexpressing cytosine deaminase: a novel, tumor-selective therapy.
King I; Itterson M; Bermudes D
Methods Mol Biol; 2009; 542():649-59. PubMed ID: 19565926
[TBL] [Abstract][Full Text] [Related]
4. Bacterial vectors and delivery systems in cancer therapy.
Gardlik R; Fruehauf JH
IDrugs; 2010 Oct; 13(10):701-6. PubMed ID: 20878592
[TBL] [Abstract][Full Text] [Related]
5. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients.
Nemunaitis J; Cunningham C; Senzer N; Kuhn J; Cramm J; Litz C; Cavagnolo R; Cahill A; Clairmont C; Sznol M
Cancer Gene Ther; 2003 Oct; 10(10):737-44. PubMed ID: 14502226
[TBL] [Abstract][Full Text] [Related]
6. Bacteria in cancer therapy: a novel experimental strategy.
Patyar S; Joshi R; Byrav DS; Prakash A; Medhi B; Das BK
J Biomed Sci; 2010 Mar; 17(1):21. PubMed ID: 20331869
[TBL] [Abstract][Full Text] [Related]
7. Increasing specificity of anti-tumor therapy: cytotoxic protein delivery by non-pathogenic clostridia under regulation of radio-induced promoters.
Nuyts S; Theys J; Landuyt W; van Mellaert L; Lambin P; Anné J
Anticancer Res; 2001; 21(2A):857-61. PubMed ID: 11396175
[TBL] [Abstract][Full Text] [Related]
8. Live bacteria as the basis for immunotherapies against cancer.
Chabalgoity JA; Dougan G; Mastroeni P; Aspinall RJ
Expert Rev Vaccines; 2002 Dec; 1(4):495-505. PubMed ID: 12901588
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for cancer: dairy bacteria as delivery vectors.
Tangney M
Discov Med; 2010 Sep; 10(52):195-200. PubMed ID: 20875340
[TBL] [Abstract][Full Text] [Related]
10. Optimization of tumor-targeted gene delivery by engineered attenuated Salmonella typhimurium.
Mei S; Theys J; Landuyt W; Anne J; Lambin P
Anticancer Res; 2002; 22(6A):3261-6. PubMed ID: 12530073
[TBL] [Abstract][Full Text] [Related]
11. Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors.
Yazawa K; Fujimori M; Amano J; Kano Y; Taniguchi S
Cancer Gene Ther; 2000 Feb; 7(2):269-74. PubMed ID: 10770636
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticles for delivery of chemotherapeutic agents to tumors.
Vijayaraghavalu S; Raghavan D; Labhasetwar V
Curr Opin Investig Drugs; 2007 Jun; 8(6):477-84. PubMed ID: 17621878
[TBL] [Abstract][Full Text] [Related]
13. Clostridium as a tumor-specific delivery system of therapeutic proteins.
Theys J; Landuyt AW; Nuyts S; Van Mellaert L; Lambin P; Anné J
Cancer Detect Prev; 2001; 25(6):548-57. PubMed ID: 12132875
[TBL] [Abstract][Full Text] [Related]
14. [Application of microorganisms as delivery vehicles in cancer gene therapies].
Łepeta K; Łasica AM; Jagusztyn-Krynicka EK
Postepy Biochem; 2012; 58(3):314-26. PubMed ID: 23373417
[TBL] [Abstract][Full Text] [Related]
15. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation.
Thamm DH; Kurzman ID; King I; Li Z; Sznol M; Dubielzig RR; Vail DM; MacEwen EG
Clin Cancer Res; 2005 Jul; 11(13):4827-34. PubMed ID: 16000580
[TBL] [Abstract][Full Text] [Related]
16. [Anaerobic bacteria as a gene delivery system for breast cancer therapy].
Fujimori M
Nihon Rinsho; 2008 Jun; 66(6):1211-8. PubMed ID: 18540373
[TBL] [Abstract][Full Text] [Related]
17. Antitumor therapeutic effects of Salmonella typhimurium containing Flt3 Ligand expression plasmids in melanoma-bearing mouse.
Yoon WS; Choi WC; Sin JI; Park YK
Biotechnol Lett; 2007 Apr; 29(4):511-6. PubMed ID: 17235489
[TBL] [Abstract][Full Text] [Related]
18. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium.
Clairmont C; Lee KC; Pike J; Ittensohn M; Low KB; Pawelek J; Bermudes D; Brecher SM; Margitich D; Turnier J; Li Z; Luo X; King I; Zheng LM
J Infect Dis; 2000 Jun; 181(6):1996-2002. PubMed ID: 10837181
[TBL] [Abstract][Full Text] [Related]
19. Genetically engineered Salmonella Typhimurium: Recent advances in cancer therapy.
Liang K; Liu Q; Li P; Luo H; Wang H; Kong Q
Cancer Lett; 2019 Apr; 448():168-181. PubMed ID: 30753837
[TBL] [Abstract][Full Text] [Related]
20. Salmonella and cancer: from pathogens to therapeutics.
Chorobik P; Czaplicki D; Ossysek K; Bereta J
Acta Biochim Pol; 2013; 60(3):285-97. PubMed ID: 23828775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
